Mandar Paradkar, MBBS, DCH, MPH

CRS:

BJMC

Role:

InvestigatorsClinical

Position:

Study Coordinator

Dr. Paradkar is Study Coordinator at the Byramjee Jeejeebhoy Government Medical College Clinical Research Site (BJGMC-CRS) in Pune, India. He coordinates Tuberculosis Research by the Indo-US Medical Partnership (CTRIUMPh), and upcoming pediatric TB studies: SHINE and TBM Kids trial. He is a pediatrician by training and successfully completed the full time Master of Public Health degree through Cardiff University, UK, under the prestigious Commonwealth Scholarship Program in November, 2015. He rejoined the site in role of study coordinator December 2015.

In his current role, he coordinates the study activities for adult and pediatric TB study teams at the site. These activities involve regulatory documentation and reporting to the regulatory bodies at the site, recruitment of participants, ensuring the conduct of study procedures are in accordance with the study protocol, staff training, QC procedures, and regular communication with the CRS leadership, study laboratories, BJMC faculty, local authorities for National TB control programme (RNTCP) and the protocol team on relevant subjects. His research interests are clinical epidemiology of pediatric TB and HIV-TB coinfection and aims for research and publications in this subject area.

He completed his medical education in 2007 followed by pediatric post-graduation in 2009, and he worked as a pediatric intensive care registrar at Deenanath Mangeshkar Hospital, a tertiary care hospital in Pune, for a short tenure. He then joined the BJMC-CRS in 2011 and worked for four years as a pediatric research clinician for various HIV studies, including the PROMISE study under NIH’s IMPAACT trial network. He also assisted in adult cryptococcal meningitis study under NIH’s ACTG trial network.

Dr. Paradkar was selected as the New Investigator awardee for year 2011-12 by the IMPAACT network and received mentorship during the award year by Dr. Charles Mitchel (US based IMPAACT investigator). This award included participation on a network protocol development team (Dose finding, safety, and tolerance study of Raltegravir containing antiretroviral therapy in children), participation on the IMPAACT HIV complications scientific committee, and a grant award for research or training purposes. Dr. Paradkar completed the Clinical Vaccine Trials and Good Clinical Practice certificate course from Johns Hopkins University, attended the annual IMPAACT network meetings in Washington, DC, in 2011 and 2012.

  • Member, ACTG TB Meningitis Working Group (Oct 2017)

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

P1108: A Phase I/II, Open-Label, Single Arm Study to...

This purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of bedaquiline (BDQ) in...

Read More

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More

A5349: Rifapentine-containing treatment shortening regimens...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

Read More

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More